FMR LLC (Trades, Portfolio) Transaction Overview - FMR LLC (Trades, Portfolio) sold 3,605,932 shares of Fulcrum Therapeutics Inc (FULC) on September 30, 2024, reducing its holdings to 1,724,014 shares [1] - The shares were traded at $3.57, reflecting a strategic adjustment in the firm's portfolio [1] - This transaction reduced FMR LLC's stake in Fulcrum Therapeutics to 2.76% [5] FMR LLC (Trades, Portfolio) Background - FMR LLC, also known as Fidelity, was established in 1946 and has a strong focus on growth potential and innovative investment strategies [2] - The firm manages a vast portfolio with significant holdings in technology and healthcare sectors, including major companies like Apple Inc and Microsoft Corp [2] - As of June 30, 2024, FMR LLC's top holdings include NVIDIA Corp ($129.0B), Microsoft Corp ($96.8B), and Apple Inc ($72.8B) [3] Fulcrum Therapeutics Inc Overview - Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for complex diseases such as muscular dystrophy and sickle cell disease [4] - The company went public on July 18, 2019, and currently has a market capitalization of $224.955 million [4] - Fulcrum's stock price is $3.605, significantly below its GF Value of $48.74 [4] Market Performance and Valuation of Fulcrum Therapeutics - Fulcrum Therapeutics has experienced a 50% year-to-date price decrease and a 75.14% drop since its IPO [6] - The company's GF Score is 54/100, indicating poor future performance potential [6] - Fulcrum ranks 1/10 in Profitability and 0/10 in Growth, further highlighting its challenges [6] Biotechnology Sector and FMR LLC's Strategy - FMR LLC has historically allocated a significant portion of its portfolio to the healthcare sector, with biotechnology being a key focus [7] - The recent reduction in Fulcrum Therapeutics holdings suggests a possible realignment of FMR LLC's investment strategy within the volatile biotechnology sector [7] Future Outlook for Fulcrum Therapeutics - Analysts remain cautious about Fulcrum Therapeutics' future due to its financial health and market challenges [8] - The strategic reduction by FMR LLC may indicate broader concerns about the biotechnology sector's near-term prospects [8] Conclusion - The transaction by FMR LLC represents a significant realignment of its investment in Fulcrum Therapeutics, reflecting the firm's adaptive portfolio management strategy [9] - This move is indicative of FMR LLC's response to the evolving dynamics of the biotechnology sector [9]

A downtrend has been apparent in Fulcrum Therapeutics, Inc. (FULC) lately with too much selling pressure. The stock has declined 57.5% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical in ...

Fulcrum Therapeutics, Inc. (FULC) has been beaten down lately with too much selling pressure. While the stock has lost 65.6% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum ...

NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC). Investors who purchased Fulcrum securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FULC. Investigation Details On September 12, 2024, Fulcrum announced that "its Phase 3 REACH trial evaluating losma ...

Shares of Fulcrum Therapeutics, Inc. (FULC) plunged 61.1% on Sept. 12 after the company announced disappointing top-line data from the phase III REACH study, which evaluated its pipeline candidate, losmapimod, for treating patients with facioscapulohumeral muscular dystrophy (FSHD), a rare and debilitating disease. Currently, there are no treatments approved for the given indication. The study did not meet its primary endpoint as treatment with losmapimod failed to demonstrate a change from baseline in rela ...

CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a series of investor meetings at the following conferences: Wells Fargo Healthcare Conference Wednesday, September 4, 2024 Boston, MA Morgan Stanley 22nd Annual Global Healthcare Conference Frid ...

Fulcrum Therapeutics, Inc. (FULC) closed the last trading session at $9.42, gaining 6.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $16.11 indicates a 71% upside potential. The mean estimate comprises nine short-term price targets with a standard deviation of $5.78. While the lowest estimate of $5 indicates a 46.9% decline from the current price level, the most optimistic anal ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q2 2024 Results Conference Call July 31, 2024 8:00 AM ET Company Participants Alex Sapir - CEO and President Alan Musso - CFO Iain Fraser - SVP of Early Development Conference Call Participants Corinne Johnson - Goldman Sachs Kristen Kluska - Cantor Fitzgerald Joseph Schwartz - Leerink Partners Dae Gon Ha - Stifel Gregory Renza - RBC Capital Markets Matthew Biegler - Oppenheimer Operator Good morning and welcome to Fulcrum's Therapeutics Second Quarter 2024 Financial ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-4839948 (State or other juri ...

• Cash Position: As of June 30, 2024, cash, cash equivalents, and marketable securities were $273.8 million, as compared to $236.2 million as of December 31, 2023. The increase in our cash position is due to the $80.0 million upfront payment received from Sanofi in the second quarter of 2024, partially offset by cash used to fund our operating activities in 2024. • Collaboration Revenue: Collaboration revenue was $80.0 million for the three months ended June 30, 2024, as compared to $0.9 million for the thr ...